Endovascular Today
VerifiedMagazine
Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurointerventionists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.
Endovascular Today is published 12 times per year and also offers a free biweekly eNewsletter, advising of recent FDA approvals, clinical trial updates, Medicare coverage news, and new product launches. Please visit our subscriptions page for more information on receiving Endovascular Today.
Actions
Media Outlet details
| Scope | Trade/B2B, Consumer |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesGore’s Pivotal Trial of Excluder IBE Plus Stent Graft Begins Enrollment
KEY TAKEAWAYS The pivotal IBE Plus trial has begun enrollment to evaluate Gore’s investigational Excluder IBE Plus stent graft, an iliac branch endoprosthesis. The prospective, nonrandomized study will enroll patients in two arms at approximately 30 United States sites, with follow-up through 5 years. The device is being studied for endovascular treatment of aortoiliac and common iliac artery aneurysms in the United States.
Medtronic’s In.Pact BTK DCB Earns FDA Breakthrough Device Designation
KEY TAKEAWAYS The FDA granted Breakthrough Device designation for Medtronic’s investigational In.Pact BTK drug-coated balloon catheter. Medtronic plans to evaluate the device in the randomized IN.PACT BTK DELTA pivotal study. Eric Secemsky, MD, will serve as Global Principal Investigator of the planned study.
Terumo Neuro to Acquire Arsenal Medical
KEY TAKEAWAYS Terumo Neuro has agreed to acquire Arsenal Medical, developer of the investigational NeoCast liquid embolic technology. NeoCast is being evaluated for MMA embolization in patients with subacute and chronic subdural hematoma. The RADIANT pivotal trial comparing NeoCast with the Onyx liquid embolic system (Medtronic) has begun enrollment.
AMA Panel Creates Category I CPT Codes for Renal Denervation
KEY TAKEAWAYS The AMA CPT Editorial Panel has created two category I CPT codes for percutaneous transcatheter renal sympathetic denervation procedures. The codes, currently identified as 37X47 and 37X48, are scheduled to take effect January 1, 2028. The codes apply to renal denervation procedures for uncontrolled hypertension performed with FDA-approved systems including Medtronic’s Symplicity Spyral and Recor’s Paradise.
Inquis Launches Aventus Thrombectomy Catheter With 360° Directional Aspiration for PE
KEY TAKEAWAYS Inquis Medical announced the United States commercial launch of its latest Aventus catheter after it received FDA 510(k) clearance in July 2026. The catheter provides 360° directional aspiration and incorporates real-time tissue sensing and autologous blood return. The first-in-human PE procedure with the new catheter was performed by Austin Bourgeois, MD, at Huntsville Hospital.
TriSalus Life Sciences’ TriNav Advance Cleared by FDA for Liver Embolization
KEY TAKEAWAYS TriSalus Life Sciences received FDA 510(k) clearance for the TriNav Advance pressure-enabled drug delivery device for liver-directed therapy. The device is designed to support embolization procedures involving small, distal vessels when paired with a compatible microcatheter. TriSalus plans a limited market release of TriNav Advance in the coming weeks. September 29, 2026—TriSalus Life Sciences, Inc.
VS3 System Receives FDA Breakthrough Device Designation to Treat Debilitating Pulsatile Tinnitus
KEY TAKEAWAYS The FDA granted Breakthrough Device designation to the investigational VS3 system. The designation was based on evidence indicating the system has the potential to resolve pulsatile tinnitus associated with venous sinus stenosis. The self-expanding device is designed to conform to the venous sinus and treat intrinsic and extrinsic stenoses.
Achieving Durable Results Above the Knee
The femoropopliteal segment is the longest arterial segment in the leg, subject to flexion, torsion, and compression, and it carries a high burden of calcification and long-segment disease. Restoring flow is rarely the whole objective. The harder question is how to restore it in a way that can be maintained and revised when it eventually fails.
Pedal Disease: Can Vessel Remodeling Improve Distal Revascularization?
Case Presentation A male diabetic patient in his mid-60s with a history of prior lower extremity intervention presented with a new, nonhealing toe wound (Figure 1A). Although a previous toe wound and amputation had healed following revascularization, the posterior tibial (PT) artery had subsequently reoccluded. Angiography demonstrated significant tibial and inframalleolar disease with essentially single-vessel runoff through the anterior tibial (AT) artery (Figure 1B-1D).
iVascular’s Amber Liquid Embolic Evaluated in Premarket OPAL Study
KEY TAKEAWAYS Phase 2 OPAL data included 70 patients treated with iVascular’s Amber liquid embolic. Total occlusion was achieved in 98.6% of patients, with no microcatheter entrapment or material migration reported. OPAL is a prospective, multicenter premarket study conducted at 11 centers in Spain. September 29, 2026—iVascular announced new phase 2 data from the OPAL study of Amber, the company’s liquid embolic.